Min Liu

Min Liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2020 in Medical Science Monitor
Verified
Journal Article
Closed access
TXTian Xu
Tian Xu
QWQingguo Wang
Qingguo Wang
MLMin Liu
Min Liu
Background: The aim of this study was to identify the bioactive ingredients of Huangqin-Baishao herb pair and to reveal its anti-cancer mechanisms through a pharmacology approach. Material/Methods: Detailed information on compounds in the HQ-BS herb pair was obtained from the Traditional Chinese medicine systems pharmacology (TCMSP) and screened by the criteria of OB >= 30% and DL >= 0.18. A systematic drug targeting model (SysDT) was used for compound targets prediction, and then the targets were analyzed for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. The protein-protein interaction (PPI) network of HQ-BS targets was constructed, after identifying core networks through Cytoscape plugins. Results: We found 47 bioactive compounds of HQ-BS and 107 human-derived targets. A compound target network and a target signal pathway network were constructed and used for topological analysis. Kaempferol, beta-sitosterol, stigmasterol, wogonin, and oroxylin-a were identified as core compounds and pathways in cancer. The calcium signaling pathway, PI3K-Akt signaling pathway, TNF signaling pathway, chemical carcinogenesis, estrogen signaling pathway, proteoglycans in cancer, HIF-1 signaling pathway, thyroid hormone signaling pathway, VEGF signaling pathway, small cell lung cancer, prostate cancer, colorectal cancer, NOD-like receptor signaling pathway, and T cell receptor signaling pathway were found to be potential signals of HQ-BS in treating cancer. Through PPI network analysis, TNF signaling pathway, tryptophan metabolism, proteoglycans in cancer, cell cycle, and chemical carcinogenesis sub-networks were obtained. Conclusions: HQ-BS contains various bioactive compounds, including flavonoids, phytosterols, and other compounds, and these compounds can inhibit or activate multiple targets and pathways against cancer.

1 July 2020 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
JYJun-Tang Yan
Jun-Tang Yan
QWQing-Guo Wang
Qing-Guo Wang
XLXiao-Qian Liu
Xiao-Qian Liu
BLBin Li
Bin Li
YRYi Ru
Yi Ru
XLXin Li
Xin Li
Background: Chinese medicine (CM) classifies psoriasis vulgaris into three syndromes: blood-heat syndrome (BHS), blood-stasis syndrome (BSS), and blood-dryness syndrome (BDS). The levels of several immunological serum markers in BHS have been established. We aimed to investigate the immune status of patients with psoriasis vulgaris of BSS and BDS. Methods: Seven databases were searched, covering nearly 40 years. Fifteen studies including 957 individuals (386 patients with psoriasis vulgaris of BSS, 233 patients with BDS, and 338 healthy controls) were identified. Differences in interleukin (IL) levels between subjects and controls were pooled as mean differences (MDs) with 95% confidence intervals (CI) using a random-effects model. Results: For BSS, interferon (IFN)-γ (MD 3.85, 95% CI: 1.27 to 6.44), tumor necrosis factor (TNF)-α (MD 1.71, 95% CI: 0.70 to 2.72), IL-4 (MD 7.66, 95% CI: 4.67 to 10.65), IL-17 (MD 5.06, 95% CI: 0.28 to 9.85), IL-6 (MD 99.34, 95% CI: 45.84 to 152.84), and IL-22 (43.88, 95% CI: 28.17 to 59.59) levels were significantly higher in patients than in controls, while pooled IL-10 levels were lower in patients (MD −10.33, 95% CI: −12.03 to −8.63). The MD in IL-8 levels between cases and controls was not significant. Subjects with BDS showed higher levels of IFN-γ (MD 2.33, 95% CI: 0.22 to 4.45), TNF-α (MD 2.33, 95% CI: 1.26 to 3.40), and IL-23 (MD 46.18, 95% CI: −7.60 to 99.97) and lower levels of IL-4 levels (MD −2.47, 95% CI: −4.78 to −0.15) than did controls. The MDs in IL-17, IL-6, and IL-8 levels were not statistically significant. Conclusions: Our pooled analysis suggests that the levels of several ILs are specifically altered in BSS and BDS. Larger, well designed, controlled studies are needed to confirm these results and fully clarify these effects.

30 September 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JWJianing Wang
Jianing Wang
FLFeiyin Liu
Feiyin Liu
QLQianwen Lou
Qianwen Lou
YYYinan Yang
Yinan Yang
MLMin Liu
Min Liu
Objective: To evaluate the cutaneous efficacy and glucocorticoid-sparing effects of anifrolumab in systemic lupus erythematosus (SLE) and to assess composite disease activity and flare-related and safety outcomes. Methods: PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov were searched through 20 April 2026. Meta-analyses were restricted to randomized controlled trials comparing intravenous anifrolumab 300 mg every 4 weeks plus standard therapy with placebo plus standard therapy; TULIP-SC and overlapping reports were synthesized narratively. Risk ratios (RRs) or rate ratios with 95% confidence intervals (CIs) were pooled using random-effects models in the primary analyses, with fixed-effect models applied in sensitivity analyses. Modified Hartung-Knapp-Sidik-Jonkman (HKSJ) sensitivity analyses were performed for outcomes with substantial heterogeneity and a small number of contributing studies. Risk of bias and certainty of evidence were assessed using RoB 2 and GRADE, respectively. Results: In all, 12 reports from five independent trials were included; four intravenous trials contributed up to 1,203 participants. The Week 52 CLASI-A50 estimate was based on two trials (n = 165), not the full 1,203-participant IV evidence set. Random-effects pooling showed that anifrolumab improved Week 52 CLASI-A50 response based on two trials among patients with baseline CLASI-A ≥ 10 (RR 1.52, 95% CI 1.04 to 2.24), sustained oral glucocorticoid reduction in those receiving ≥ 10 mg/day at baseline (RR 1.56, 95% CI 1.30 to 1.87), and BICLA response (RR 1.66, 95% CI 1.41 to 1.94). SRI-4 (RR 1.39, 95% CI 1.04 to 1.87; I² = 80.8%), LLDAS attainment (RR 1.80, 95% CI 1.19 to 2.73; I² = 57.2%), and annualized flare rate (rate ratio 0.65, 95% CI 0.47 to 0.91; I² = 56.5%) favored anifrolumab but were affected by heterogeneity or limited trial numbers. The incidence of any adverse events was slightly higher (RR 1.09, 95% CI 1.03 to 1.16), whereas serious adverse events and discontinuations due to adverse events did not differ significantly. Supplementary analyses of selected adverse events of clinical interest suggested an increased risk of herpes zoster (RR 3.88, 95% CI 1.70 to 8.89), although event numbers were limited and these analyses were supplementary. Modified HKSJ sensitivity analyses yielded wider intervals crossing the null for SRI-4, LLDAS, annualized flare rate, serious adverse events, and adverse events leading to discontinuation. Conclusions: Intravenous anifrolumab improved Week 52 CLASI-A50 response in the two contributing trials of patients with baseline CLASI-A ≥ 10 and facilitated sustained glucocorticoid reduction in the prespecified glucocorticoid subgroup. DerSimonian-Laird point estimates for secondary efficacy outcomes generally favored anifrolumab, but the HKSJ sensitivity analyses for heterogeneous outcomes and the limited safety data warrant cautious interpretation. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261367219.

28 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
CCcongai cong chen
congai cong chen
XDXin Du
Xin Du
CLChangxiang Li
Changxiang Li
BRBeida Ren
Beida Ren
NDNan Deng
Nan Deng
MLMin Liu
Min Liu
Background: Ischemic stroke is a common clinical disease limited by its time window for treatment. In addition to its high mortality rate, only one treatment currently exists for ischemic stroke. Nonetheless, traditional Chinese medicine is often used as a reatment for the disease. Bezoar is a multi-functional drug that has been demonstrated to be effective for the treatment of ischemic stroke. However, its mechanism of action is yet to be fully elucidated. Based on network pharmacology, we explored the potential mechanism of action of bezoar. Symmap and literature data mining methods were used to obtain the target of bezoar. The mechanism of bezoar for the treatment of ischemic stroke was identified and ischemic stroke-related targets were retrieved using DrugBank, Online Mendelian Inheritance in Man, and Therapeutic Target Database. Protein-protein interaction networks were constructed using the Cytoscape plugin, BisoGenet, and analysed by topological methods. Gene Ontology and Kyoto Encyclopaedia of Genes and Genomes pathway enrichment were carried out via the Database for Annotation, Visualization, and Integrated Discovery server. We obtained 48 potential targets and 3 signalling pathways, including mitogen-activated protein kinase, hypoxia-inducible factor-1, and tumour necrosis factor signalling pathways. The mechanism of action of bezoar on ischemic stroke involves multiple targets and signalling pathways. Our research provides a network pharmacology framework for future Chinese medicinal research.